Moore RD - Search Results

1

Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Wang L, Krebs E, Min JE, Mathews WC, Nijhawan A, Somboonwit C, Aberg JA, Moore RD, Gebo KA, Nosyk B; HIV Research Network. Wang L, et al. Among authors: moore rd. Lancet HIV. 2019 Aug;6(8):e531-e539. doi: 10.1016/S2352-3018(19)30148-1. Epub 2019 Jul 11. Lancet HIV. 2019. PMID: 31303557 Free PMC article.

2

Hepatitis C and progression of HIV disease.

Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Sulkowski MS, et al. Among authors: moore rd. JAMA. 2002 Jul 10;288(2):199-206. doi: 10.1001/jama.288.2.199. JAMA. 2002. PMID: 12095384

3

Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy.

Gebo KA, Keruly J, Moore RD. Gebo KA, et al. Among authors: moore rd. J Gen Intern Med. 2003 Feb;18(2):104-11. doi: 10.1046/j.1525-1497.2003.10801.x. J Gen Intern Med. 2003. PMID: 12542584 Free PMC article.

4

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Sethi AK, et al. Among authors: moore rd. Clin Infect Dis. 2003 Oct 15;37(8):1112-8. doi: 10.1086/378301. Epub 2003 Sep 19. Clin Infect Dis. 2003. PMID: 14523777

5

Hospitalization rates differ by hepatitis C satus in an urban HIV cohort.

Gebo KA, Diener-West M, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):165-73. doi: 10.1097/00126334-200310010-00006. J Acquir Immune Defic Syndr. 2003. PMID: 14526205

6

The HIV Research Network: a unique opportunity for real time clinical utilization analysis in HIV.

Gebo KA, Moore RD, Fleishman JA. Gebo KA, et al. Among authors: moore rd. Hopkins HIV Rep. 2003 Nov;15(6):5-6. Hopkins HIV Rep. 2003. PMID: 14974424 No abstract available.

7

Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection.

Gebo KA, Gallant JE, Keruly JC, Moore RD. Gebo KA, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1028-33. doi: 10.1097/00126334-200408150-00005. J Acquir Immune Defic Syndr. 2004. PMID: 15247555

8

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.

Karakousis PC, Moore RD, Chaisson RE. Karakousis PC, et al. Among authors: moore rd. Lancet Infect Dis. 2004 Sep;4(9):557-65. doi: 10.1016/S1473-3099(04)01130-2. Lancet Infect Dis. 2004. PMID: 15336223 Review.

9

Treatment of HIV infection in the older patient.

Gebo KA, Moore RD. Gebo KA, et al. Among authors: moore rd. Expert Rev Anti Infect Ther. 2004 Oct;2(5):733-43. doi: 10.1586/14789072.2.5.733. Expert Rev Anti Infect Ther. 2004. PMID: 15482236 Review.

10

Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy?

Himelhoch S, Moore RD, Treisman G, Gebo KA. Himelhoch S, et al. Among authors: moore rd. J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1457-63. doi: 10.1097/01.qai.0000136739.01219.6d. J Acquir Immune Defic Syndr. 2004. PMID: 15602123

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

931 results

Search Page

Filters